New Guinness® World Record – World’s Biggest Bug Hotel

DUROR, Scotland, March 31, 2022 (GLOBE NEWSWIRE) — On Monday 28th March 2022, conservation company Highland Titles achieved a new GUINNESS WORLD RECORD for the world's biggest bug/insect hotel, which means Highland Titles are "Officially Amazing!"

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c6d0e716–dbd2–4737–934d–660fac898b70

The 199.9 cubic metre structure is located on the Highland Titles Nature Reserve at Duror in the Scottish Highlands and already houses a variety of species. It breaks the previous world record of 89.37 cubic metres, which was held by the Polish Association of Developers in Warsaw, Poland.

The world record–breaking bug hotel was made using felled sitka spruce from the nature reserve, masonry bricks, bamboo canes, wood chips, forest bark, wildflower seeds, clay pipes and strawberry netting.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8f7ca5a3–5c5c–4d71–a475–daceb2ca6aff

"This record–breaking initiative is about the environmental message," says Douglas Wilson, CEO of Highland Titles. "We bought this land in 2006 when it was a poorly performing commercial forestry plantation of non–native Sitka Spruce.

"Like much of the Highlands, it was inappropriately planted in the late 1980s with no thought or consideration given to biodiversity. Using these same trees for something that puts nature first symbolises that the world has changed, and we hope our efforts will inspire others. We'd be delighted if someone beat our record in the future!"

Nature Reserve Manager, Stewart Borland, was part of a team of 7 who were involved in its construction which started in September 2021 and was completed in early March 2022. In addition to the environmental message, Mr Borland hopes that it encourages people to visit:

"In 2019, we had more than 10,000 visitors to the nature reserve from all over the world. The pandemic really put a dent in our visitor numbers, so we hope that this – together with the new track which is adored by cyclists – will encourage people to visit now that travel is opening up again. The more visitors we get, the more people can see the work that we're doing."

About Highland Titles

Highland Titles began in 2006 with a mission to conserve Scotland, one square foot at a time. The conservation project – now encompassing 5 nature reserves and over 800 acres of Scottish wilderness – is funded by selling gift–sized souvenir plots of land.

The Highland Titles community of souvenir plot owners are invited to style themselves as the Lords and Ladies of Glencoe. Over 300,000 plots of land have been sold to date.

The Highland Titles Nature Reserve near Glencoe is an official 4* tourist attraction and, according to Trip Advisor, one of the most popular nature reserves in the country.

Resources

For more information on the World's Biggest Bug Hotel, visit here

For more photographs or video content, please email support@highlandtitles.com with your email address, name and phone number

Contact

Douglas Wilson, CEO
douglas@highlandtitles.com


GLOBENEWSWIRE (Distribution ID 1000614300)

Asante Gold Announces Appointment of Executive Vice President & Country Director

VANCOUVER, British Columbia, March 31, 2022 (GLOBE NEWSWIRE) — Asante Gold Corporation (CSE:ASE | FRANKFURT:1A9 | U.S.OTC:ASGOF) ("Asante" or the "Company") is pleased to announce the appointment of Frederick Attakumah as Executive Vice President and Country Director with effect from April 1, 2022.

Mr. Attakumah holds a B.Sc. (Hons) in Electrical Engineering from the Kwame Nkrumah University of Science and Technology (Ghana) and a Master of Business Administration degree from the Henley Business School (UK). He has thirty years' experience in the mining industry spanning project development, operations management, sustainability, and corporate affairs.

Prior to joining Asante, Mr. Attakumah was the Executive Vice President and Managing Director of Asanko Gold Ghana Limited. He has also held several senior executive roles including Managing Director of AngloGold Ashanti (Ghana) Limited and Vice President of Sustainability for AngloGold Ashanti's operations in Ghana.

At the industry level, he held the position of First Vice President of the Ghana Chamber of Mines and concurrently served as a member of the Governing Council of the Private Enterprise Federation of Ghana (PEF). He has also served as President of the Canada Ghana Chamber of Commerce which is focused on building bilateral private sector relationships between Ghana and Canada. Mr. Attakumah has been a strong advocate for the positive role of the mining industry in the socio–economic development of African countries and the criticality of a multi–stakeholder approach in realizing this vision. He has contributed to several local and international panels, including the Mining Indaba, on this topic.

Commenting on the appointment, Dave Anthony, CEO of Asante stated, "We are delighted to welcome Frederick as Executive Vice President and Country Director of Asante. The extraordinary capacity this appointment adds to our team supports our intention to develop a first tier mining company in West Africa. His proven leadership capacity, skill set and ability to engage key stakeholders will be critical to the further development and growth of Asante."

In connection with the appointment of Frederick Attakumah, the Company has granted 1,000,000 incentive stock options to purchase common shares of the Company exercisable at $1.75 per share for a term of five years, such options to vest one–quarter on the date of grant and one quarter in each of six, nine and 12 months subject to the provisions of the Company's Equity Incentive Plan.

About Asante Gold Corporation

Asante is a gold exploration, development, and operating company with a high–quality portfolio of projects in Ghana, Africa's largest and most reliable gold producer. Asante is currently focused on developing to production its Bibiani and Kubi Gold mines located on the prolific Bibiani and Ashanti Gold Belts. Asante has an experienced and skilled team of mine finders, builders and operators, with extensive experience in Ghana.

Asante is listed on the Canadian Securities Exchange and the Frankfurt Stock Exchange and has announced plans to co–list its shares in Ghana. Asante is also exploring its Keyhole, Fahiakoba and Betenase projects for new discoveries, all adjoining or along strike of major gold mines near the centre of Ghana's Golden Triangle. Additional information is available on the Company's website at www.asantegold.com.

About the Bibiani Gold Mine

Bibiani is a historically significant gold mine situated in the western region of Ghana, with previous gold production close to 5 Moz. It is fully permitted with available mining and processing infrastructure on–site consisting of a 3 million tonne per annum mill and processing plant, and existing surface and mining infrastructure.

The Current Mineral Resource Estimate for Bibiani, as reported in the Technical Report on the Bibiani Gold Mine, Ghana, by Principal Author Ian M Glacken FAusIMM (CP), FAIG, CEng and Qualified Person Dan Bansah MSc, MAusIMM (CP), FWAIMM, MGIG, dated November 7, 2021, and filed on SEDAR, is Measured and Indicated 20.1 million tonnes at 2.71 grams of gold per tonne for 1.81 Moz of gold, plus Inferred 8.41 million tonnes at 2.78 grams of gold per tonne for 0.75 Moz of gold from an open pit mine. The Mineral Resource has been reported above a 0.65 g/t gold cut–off and has been depleted for both historical open pit and underground development as of August 31, 2017. The Bibiani Main Pit mineral resource has been prepared by Competent Persons (Optiro, 2017) using accepted industry practices and have been classified and reported in accordance with the JORC Code (JORC, 2012). There are no material differences between the definitions of Measured, Indicated and Inferred Mineral Resources under the CIM Definition Standards and the equivalent definitions in the JORC Code. The Satellite pit resource is an update completed in 2018 by Resolute Mining Limited. The Satellite pit resource is also reported above a cut–off grade of 0.65 g/t gold inside a pit shell defined at a gold price of US$1,950. Mineral resources that are not mineral reserves do not have demonstrated economic viability.

For further information please contact:

Dave Anthony, President & CEO: +1 647 382 4215 (Canada) or +233 558 799 3309 (Ghana) or dave@asantegold.com
Malik Easah, Executive Director, malik@asantegold.com
Alec Rowlands, Capital Markets Consultant, alec@asantegold.com
Valentina Gvozdeva, Manager IR, mailto:valentina@asantegold.com
Kirsti Mattson, Media Relations, kirsti.mattson@gmail.com

Cautionary Statement on Forward–Looking Statements

This news release contains forward–looking statements. Forward–looking statements involve risks, uncertainties and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward–looking statements, including statements regarding the resources, reserves, exploration results, and development program at Bibiani, including timing of future mine development and the start of production. Factors that could cause actual results to differ materially from these forward–looking statements include, but are not limited to, variations in the nature, quality and quantity of any mineral deposits that may be located, the Company's inability to obtain any necessary permits, consents or authorizations required for its planned activities, and the Company's inability to raise the necessary capital or to be fully able to implement its business strategies. The reader is referred to the Company's public disclosure record which is available on SEDAR (www.sedar.com). Although the Company believes that the assumptions and factors used in preparing the forward–looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except as required by securities laws and the policies of the Canadian Securities Exchange, the Company disclaims any intention or obligation to update or revise any forward–looking statement, whether as a result of new information, future events or otherwise.

LEI Number: 529900F9PV1G9S5YD446. Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.


GLOBENEWSWIRE (Distribution ID 8513527)

Vita Inclinata Expands Into the Middle East Market

BROOMFIELD, Colo., WASHINGTON, and DUBAI, United Arab Emirates, March 31, 2022 (GLOBE NEWSWIRE) — Vita Inclinata (Vita), developer and producer of helicopter and crane load stabilization and precision hardware, today announced ALEC Engineering and Contracting (ALEC) piloted the company's Vita Lifting System in Q4, 2021. ALEC selected Vita Inclinata's Lifting System for field trial after a comprehensive evaluation. The Vita system was initially inspected in the UAE by Astron Certification, in accordance with International and UAE lifting standards.

As a leading construction company in the GCC, ALEC owns and operates its own equipment including 33 cranes, 122 pieces of heavy plant equipment, and 8 hoists. The company has successfully delivered over 100 complex projects across diverse sectors including airports, retail spaces, hotels & resorts, high–rise buildings, and themed projects. The company's focus on pioneering digital technologies enables ground–breaking innovation, increased efficiency, and collaboration with building""technology partners such as Vita. The Vita partnership enables ALEC to gather data on lift speed, ease of placement, time savings, and safety/reduced risk capabilities.

"Dubai's construction projects are constantly challenged with extreme heat and wind conditions that often create significant safety hazards and extended timelines," said Caleb Carr, Vita Inclinata CEO. "We are honored ALEC selected our lift system for evaluation and excited to see that our technology performed so well in these high–profile evaluations."

After a brief training and certification program, ALEC took control of the Vita Load Pilot (VLP) and conducted a multi–week field trial on two separate sites in the UAE. Although the smallest of Vita's industrial systems, the VLP was pushed to its functional limits and performed flawlessly""providing remote, precision load control without taglines at heights over 200m, traversing or "walking" around corners, and in high–wind conditions.

"As a multi–disciplinary company, ALEC has built a reputation for solving problems by using innovation to help execute complex projects on time, on budget, and safely," said Imad Itani, Innovation Manager for ALEC. "We were impressed by the Vita Lifting System's rugged, easy–to–use, semi–automated load control technology that will improve operations by improving efficiency, reducing downtime caused by high winds, minimizing risk to load and life on the worksite, as well as driving bottom–line savings."

About ALEC

ALEC Engineering and Contracting LLC (ALEC), part of the Investment Corporation of Dubai (ICD), is a large construction company with related businesses operating in the GCC with a presence in Africa. ALEC has consistently evolved and grown over the last 20 years to become a trusted partner for the execution of complex and iconic construction projects. The company builds and provides construction solutions to exceed our clients' expectations for quality, safety, functionality, and aesthetics. We have received numerous awards for excellence, quality, safety, reliability, and sustainability and are recognized as a leading contractor in the region. For more information, visit www.alec.ae

About Vita Inclinata

A friend's death during a rescue operation""with a helicopter close but unable to stabilize due to weather and terrain""was the genesis of Vita Inclinata. Founded in 2015 as a way to solve a real problem, Vita today controls chaotic swinging and spin and adds safety and precision for rotor–wing and fixed–wing aircraft and cranes. With the mission of "Bring them home, every time," Vita's technology changes the narrative while saving lives, time, and money across industries, including search and rescue, military, firefighting, public safety, construction, wind energy, and oil and gas. The company is headquartered in Broomfield, Colorado, with offices in Washington, DC, and Huntsville, Alabama. For more information, please visit www.vitatech.co.

For more information, contact:
Betsey Rogers
BridgeView Marketing
603–821–0809
betsey@bridgeviewmarketing.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/94d125ca–41e8–4266–ab2a–7586af06767f


GLOBENEWSWIRE (Distribution ID 8511457)

Adagio Therapeutics Announces ADG20 (adintrevimab) is the First Monoclonal Antibody to Meet Primary Endpoints with Statistical Significance Across Pre- and Post-exposure Prophylaxis and Treatment for COVID-19 and Plans to Seek U.S. Emergency Use Authorization

Risk of symptomatic COVID–19 was reduced by 71% compared to placebo in pre–exposure prophylaxis and 75% compared to placebo in post–exposure prophylaxis

Risk of hospitalization or death in participants with mild to moderate COVID–19 was reduced by 66% compared to placebo in the primary efficacy analysis population and by 77% compared to placebo in participants who received treatment within three days of symptom onset

Full year and fourth quarter 2021 financial results reported; $591 million in cash and investments expected to be sufficient to fund operations into second half of 2024

WALTHAM, Mass., March 30, 2022 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical–stage biopharmaceutical company focused on the discovery, development and commercialization of antibody–based solutions for infectious diseases, reported that the primary endpoints were met with statistical significance for all three indications in the company's ongoing global Phase 2/3 clinical trials evaluating its investigational drug adintrevimab (ADG20) as a pre–and–post–exposure prophylaxis (EVADE) and treatment (STAMP) for COVID–19. EVADE and STAMP were primarily conducted during a time when pre–Omicron SARS–CoV–2 variants were dominant. Following the emergence of the Omicron variant, in a pre–specified exploratory analysis in a subset of the pre–exposure cohort, a clinically meaningful reduction in cases of symptomatic COVID–19 was observed with adintrevimab compared to placebo. Across both trials, a single intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo. Based on these data, Adagio plans to engage with the U.S. Food and Drug Administration (FDA) and to submit an Emergency Use Authorization (EUA) application in the second quarter of 2022 for adintrevimab for both the prevention and treatment of COVID–19.

In addition, Adagio provided an update on its ongoing Phase 1 study evaluating adintrevimab at higher doses and on research activities related to adintrevimab re–engineering and the identification of new antibodies to potentially address COVID–19 and other viruses.

"COVID–19 continues to pose significant challenges globally as waning immunity combined with the emergence of resistant variants has led to ongoing waves of disease. We believe that a suite of options "" spanning prophylaxis and treatment "" is needed to effectively address this virus as it continues to evolve, and these data give us confidence in the potential role adintrevimab can play in physicians' arsenals," said David Hering, MBA, interim chief executive officer and chief operating officer of Adagio. "Based on the data from both EVADE and STAMP, including the impacts observed in preliminary analyses from participants enrolled after the emergence of the Omicron variant, our team is initiating discussions with the FDA and preparing an EUA submission for adintrevimab. With more than one million doses of adintrevimab secured for 2022 and a solid financial position expected to take us into the second half of 2024, we are optimistic about the road ahead and the impact adintrevimab could have for the many people around the globe, particularly those at high risk with co–morbidities, who continue to need options."

Michael Ison, M.D., M.S., professor of Medicine in the Division of Infectious Diseases and of Surgery in the Division of Organ Transplantation, Northwestern University Feinberg School of Medicine, added, "the compelling data generated on adintrevimab in both of Adagio's clinical trials represent an important step toward further addressing the continuation of the COVID–19 pandemic. I am particularly encouraged by the consistent treatment effect observed across all three clinical settings and patient subpopulations, and the favorable safety profile, with just a single dose and convenient IM delivery for all patients. The risk–reduction in the post–exposure prophylaxis setting regardless of serostatus translates to real–world use when clinicians might not know the vaccination or prior infection status of their patients. In the STAMP trial, adintrevimab showed prevention of hospitalization and death in the face of the "highest–risk' variant (Delta) to–date."

EVADE Preliminary Data
EVADE is a global, multi–center, double–blind, placebo–controlled Phase 2/3 clinical trial evaluating adintrevimab at the 300mg IM dose in two independent cohorts for the prevention of COVID–19. The study includes a pre–exposure prophylaxis (PrEP) cohort and a post–exposure prophylaxis (PEP) cohort. The study population is comprised of adults and adolescents at risk of SARS–CoV–2 infection due to reported recent exposure or whose circumstances placed them at increased risk of acquiring SARS–CoV–2 infection and developing symptomatic COVID–19.

In the primary efficacy analysis of the PrEP cohort, adintrevimab was associated with a lower incidence of symptomatic COVID–19 compared with placebo through month three or the emergence of Omicron, whichever was earlier (12/730, 1.6% vs. 40/703, 5.7%, respectively). The standardized risk difference was –4.0% (95% CI ""6.0, –2.1; p <0.0001), demonstrating a 71% relative risk reduction in favor of adintrevimab through three months. There were five (0.7%) COVID–19 related hospitalizations in the placebo group compared to none in the adintrevimab group. In a pre–specified exploratory analysis of the PrEP cohort, which included 402 participants (196 and 206 in the adintrevimab and placebo groups, respectively) following the emergence of Omicron (BA.1), a clinically meaningful reduction in cases of symptomatic COVID–19 was observed with adintrevimab, as compared to placebo. Adintrevimab was associated with a relative risk reduction of 59% and 47% with a median follow–up duration of 56 and 77 days, respectively (nominal p <0.05).

In the primary efficacy analysis in the PEP cohort, adintrevimab met statistical significance and was associated with a lower incidence of symptomatic COVID–19 through day 28 compared with placebo (3/173, 1.7% vs. 12/175, 6.9%, respectively). The standardized risk difference was –4.9% (95% CI: –8.8, –1.0; p=0.0135), demonstrating a 75% relative risk reduction in favor of adintrevimab through 28 days. There were two (1.1%) COVID–19 related hospitalizations in the placebo group compared to none in the adintrevimab group.

In the EVADE cohorts across 1,239 adintrevimab–treated participants with a median range of follow up of 140 days for the PrEP cohort and 126 days for the PEP cohort as of the March 2, 2022, data cut off, the safety profile was similar to that of placebo. The incidence of adverse events (AEs), including serious adverse events (SAEs), was similar between adintrevimab and placebo groups. No study drug related SAEs, including deaths, were reported. The most frequently reported AEs were injection–site reactions, the majority of which were mild or moderate in severity and occurred with similar frequency in both groups.

STAMP Preliminary Data
STAMP is a global, multi–center, double–blind, placebo–controlled Phase 2/3 clinical trial evaluating adintrevimab at the 300mg IM dose in patients with mild to moderate COVID–19 who are at high risk for disease progression. Adintrevimab was associated with a statistically significant lower incidence of COVID–19 related hospitalization or all cause death through day 29 compared with placebo (8/169, 4.7% vs. 23/167, 13.8%), with a standardized risk difference of –8.6% (95% CI: –14.65, –2.57; p=0.0052), demonstrating a 66% relative risk reduction in favor of adintrevimab. There was one death (0.6%) in the adintrevimab group, compared with six deaths (3.6%) in the placebo group through day 29. In patients treated within three days of symptom onset (adintrevimab n=91, placebo n=85), adintrevimab reduced the risk of COVID–19 hospitalization or death from any cause by 77% compared to placebo. STAMP enrolled 63 participants (29 in the adintrevimab group and 34 in the placebo group) with COVID–19 infection with the Omicron SARS–CoV–2 variant. There were two events of COVID–19 related hospitalization and no deaths through day 29 among the patients with the Omicron variant, and both events of hospitalization occurred in the placebo group.

In STAMP, across 192 adintrevimab–treated participants with a median follow up of 73 days in the adintrevimab group as of the February 2, 2022, data cut off, the incidence of AEs, including SAEs, was lower in the adintrevimab group. No study drug related SAEs, including deaths, were reported. The most frequently reported AEs were injection–site reactions, all of which were mild or moderate in severity and occurred with similar frequency in both groups.

"On behalf of the entire Adagio team, I'd like to thank the numerous investigators, clinical teams and, most importantly, the patients, families and caregivers for their participation in our clinical trials. We are encouraged by the data and look forward to submitting an EUA and discussing these results with the FDA and other regulatory authorities. Further, we are continuing our research efforts to improve adintrevimab activity against Omicron and identify antibodies targeting novel domains, which will provide potential additional product candidates to take into clinical development. Collectively, these efforts showcase the ability of our platform and expertise to discover, design and engineer novel antibodies, and execute global clinical trials, to potentially address infectious diseases," said Ellie Hershberger, Pharm.D., chief development officer of Adagio.

Additional Development and Research Updates
Adagio continues to leverage its platform and expertise by conducting numerous efforts to address COVID–19, other coronaviruses, influenza and other infectious diseases, including:

  • Advancing a Phase 1 trial in healthy volunteers to evaluate pharmacokinetics and safety of additional higher doses of adintrevimab to supplement the data generated to date, which has evaluated doses up to 600mg IM. Preliminary safety data through two weeks post–dosing suggest a favorable safety profile at the 1200mg dose administered with IM injection or intravenously (IV).
  • Ongoing efforts to modify adintrevimab to improve binding to the Omicron subvariants (BA.1 and BA.2) in order to enhance neutralization potency while retaining the broad neutralization observed in vitro against other SARS–CoV–2 variants of concern. Re–engineered variants of ADG20 show over 100–fold improvement in binding and up to 40–fold enhanced neutralizing activity against the Omicron BA.1 variant while maintaining activity against all other variants of concern tested to date.
  • Ongoing discovery efforts to assess additional monoclonal antibodies from the company's proprietary library of previously isolated SARS–CoV–2 antibodies for neutralization breadth and potency, which could be developed as a standalone treatment or combination therapy. Novel antibodies isolated from Omicron breakthrough infection donors have displayed in vitro activity against the 2003 SARS virus and all SARS–CoV–2 variants of concern tested to date, including the BA.1 and BA.2 variants.
  • Continuing discovery efforts to identify novel, broadly neutralizing antibodies that target epitopes both within and outside the receptor binding domain of SARS–CoV–2 and pan betacoronavirus neutralizing antibodies.

Full Year and Fourth Quarter 2021 Financial Results

  • Cash Position and Financial Guidance: Cash, cash equivalents and marketable securities were $591.4 million as of December 31, 2021. Based on current operating plans, Adagio expects its existing cash, cash equivalents and marketable securities will enable the company to fund its operating expenses and capital expenditure requirements into the second half of 2024.
  • R&D Expenses: Research and development (R&D) expenses, including in–process research and development expenses, were $68.4 million for the quarter ended December 31, 2021, and $190.4 million for the year ended December 31, 2021.
  • SG&A Expenses: Selling, general and administrative (SG&A) expenses were $14.7 million for the quarter ended December 31, 2021, and $36.5 million for the year ended December 31, 2021.
  • Net Loss: Net loss was $83.0 million, or $0.77 basic and diluted net loss per share, for the quarter ended December 31, 2021, and $226.8 million, or $5.32 basic and diluted net loss per share, for the year ended December 31, 2021.

About Adintrevimab
Adintrevimab (ADG20), Adagio's lead product candidate, is designed to be a potent, broadly neutralizing antibody for both the prevention and treatment of COVID–19, including disease caused by most variants, as either a single or combination agent. Adintrevimab is being assessed in two separate Phase 2/3 clinical trials: the EVADE trial for the prevention of COVID–19 in both the post–exposure and pre–exposure settings, and the STAMP trial for the treatment of COVID–19. Preliminary data from these trials demonstrated that in the pre–Omicron population, adintrevimab met the primary endpoints across all three indications, demonstrating statistically significant and clinically meaningful efficacy. Across each of the trials, intramuscular (IM) administration of adintrevimab at the 300mg dose had a similar safety profile to that of placebo. Adintrevimab is also being evaluated in a Phase 1 study to evaluate safety and pharmacokinetics at higher doses, and as of an interim data cut, no study drug related adverse events, serious adverse events, injection–site reactions or hypersensitivity reactions were reported across all dose levels evaluated. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established.

About Adagio Therapeutics
Adagio (Nasdaq: ADGI) is a clinical–stage biopharmaceutical company focused on the discovery, development and commercialization of differentiated products for the prevention and treatment of infectious diseases. The company is developing its lead product candidate, adintrevimab, for the prevention and treatment of COVID–19, the disease caused by the virus SARS–CoV–2 and its variants. Beyond COVID–19, Adagio is leveraging robust antibody discovery and development capabilities that have enabled expedited advancement of adintrevimab into clinical trials to develop therapeutic or preventative options for other infectious diseases, such as additional coronaviruses and influenza. Adintrevimab is an investigational monoclonal antibody that is not approved for use in any country. The safety and efficacy of adintrevimab have not been established. For more information, please visit www.adagiotx.com.

Forward Looking Statements
This press release contains forward–looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "could", "expects," "intends," "potential", "projects," and "future" or similar expressions are intended to identify forward–looking statements. Forward–looking statements include statements concerning, among other things, the timing, progress and results of our preclinical studies and clinical trials of adintrevimab, the review and analysis of data from our ongoing trials and the timing thereof, the initiation, modification and completion of studies or trials and related preparatory work, and our research and development programs; our plans related to engaging with regulatory authorities, including the timing of any regulatory submissions or applications; our pursuit of other strategies to broaden our portfolio of SARS–CoV–2 mAbs to address other SARS–CoV–2 variants of concern, including the Delta and Omicron variants; our discovery efforts to identify novel broadly neutralizing antibodies that target distinct epitopes both within and outside the receptor binding domain of SARS–CoV–2 and other beta coronaviruses; our expected cash runway; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward–looking statements and you should not place undue reliance on our forward–looking statements. These forward–looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward–looking statements, including, without limitation, the impacts of the COVID–19 pandemic on our business and those of our collaborators, our clinical trials and our financial position, unexpected safety or efficacy data observed during preclinical studies or clinical trials, the predictability of clinical success of adintrevimab based on neutralizing activity in pre–clinical studies, variability of results in models used to predict activity against SARS–CoV–2 variants of concern, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, and the uncertainties and timing of the regulatory approval process, including the outcome of our discussions with regulatory authorities concerning our Phase 2/3 clinical trials and the result of any emergency use application submission. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward–looking statements in this press release are described under the heading "Risk Factors" in Adagio's Form 10–Q for the quarter ended September 30, 2021 filed with the Securities and Exchange Commission (the "SEC"), and in our other filings with the SEC, and in Adagio's future reports to be filed with the SEC. Such risks may be amplified by the impacts of the COVID–19 pandemic. Forward–looking statements contained in this press release are made as of this date, and Adagio undertakes no duty to update such information except as required under applicable law.

Contacts
Media Contact:
Dan Budwick, 1AB
dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com


ADAGIO THERAPEUTICS, INC.
CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
(In thousands, except share and per share amounts)

December 31,
2021 2020
Assets
Current assets:
Cash and cash equivalents $ 542,224 $ 114,988
Marketable securities 49,194 ""
Prepaid expenses and other current assets 25,293 2,394
Total current assets 616,711 117,382
Property and equipment, net 83 ""
Other non–current assets 3,297 ""
Total assets $ 620,091 $ 117,382
Liabilities, Convertible Preferred Stock and Stockholders' Equity (Deficit)
Current liabilities:
Accounts payable $ 5,783 $ 8,153
Accrued expenses 56,277 4,919
Total current liabilities 62,060 13,072
Early–exercise liability 6 11
Other non–current liabilities 6 ""
Total liabilities 62,072 13,083
Commitments and contingencies
Convertible preferred stock (Series A, B and C), $0.0001 par value; no shares authorized, issued and outstanding at December 31, 2021; 12,647,934 shares authorized, issued and outstanding at December 31, 2020; aggregate liquidation preference of $0 and $169,900 at December 31, 2021 and December 31, 2020, respectively "" 169,548
Stockholders' equity (deficit):
Preferred stock (undesignated), $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding at December 31 2021; no shares authorized, issued and outstanding at December 31, 2020 "" ""
Common stock, $0.0001 par value; 1,000,000,000 shares authorized, 111,251,660 shares issued and 110,782,909 shares outstanding at December 31, 2021; 150,000,000 shares authorized, 28,193,240 shares
issued and 5,593,240 shares outstanding as of December 31, 2020
11 1
Treasury stock, at cost; 468,751 shares and 22,600,000 shares at December 31, 2021 and December 31, 2020, respectively "" (85 )
Additional paid–in capital 850,125 154
Accumulated other comprehensive loss (8 ) ""
Accumulated deficit (292,109 ) (65,319 )
Total stockholders' equity (deficit) 558,019 (65,249 )
Total liabilities, convertible preferred stock and stockholders' equity (deficit) $ 620,091 $ 117,382


ADAGIO THERAPEUTICS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(UNAUDITED)
(In thousands, except share and per share amounts)

Year Ended
December 31, 2021
Period from
June 3, 2020
(Inception) to
December 31, 2020
Operating expenses:
Research and development(1) $ 182,891 $ 21,992
Acquired in–process research and development(2) 7,500 40,125
Selling, general and administrative 36,517 3,210
Total operating expenses 226,908 65,327
Loss from operations (226,908 ) (65,327 )
Other income (expense):
Other income (expense), net 118 8
Total other income (expense), net 118 8
Net loss (226,790 ) (65,319 )
Other comprehensive income (loss):
Unrealized loss on available–for–sale securities, net of tax (8 ) ""
Comprehensive loss $ (226,798 ) $ (65,319 )
Net loss per share attributable to common stockholders, basic and diluted $ (5.32 ) $ (18.10 )
Weighted–average common shares outstanding, basic and diluted 42,621,265 3,608,491

(1) Includes related–party amounts of $4,150 for the year ended December 31, 2021 and $595 for the period from June 3, 2020 (inception) to December 31, 2020.
(2) Includes related–party amounts of $7,500 for the year ended December 31, 2021 and $39,915 for the period from June 3, 2020 (inception) to December 31, 2020.


GLOBENEWSWIRE (Distribution ID 8512575)

Umit Ciftci Named Regional Business Development Manager for Turkey

TEMECULA, Calif., March 29, 2022 (GLOBE NEWSWIRE) — Nikkiso Cryogenic Industries' Clean Energy & Industrial Gases Group ("Group"), a part of the Nikkiso Co., Ltd (Japan) group of companies, is pleased to announce that Umit Ciftci has been named Regional Business Development Manager for Turkey and the surrounding areas.

Based in Istanbul Turkey, he will be responsible for the Group's full product line, and will report to Ole Jensen, NCE&IG GmbH Germany.

Umit received a degree in Management Engineering, which provided a solid background in engineering as well as business and finance. He has over 25 years of experience in Compressed Air working at various positions including sales engineer, marketing and business line manager in Turkey and Business Development Manager in UAE for Atlas Copco.

"Umit's experience, as well as market and industry knowledge will be of great benefit to NCEIG GmbH, as we work to develop the potential opportunities in this market. We look forward to his positive contributions," according to Ole Jensen, Vice President NCEIG Europe.

With this addition, Nikkiso continues their commitment to be both a global and local presence for their customers.

ABOUT CRYOGENIC INDUSTRIES
Cryogenic Industries, Inc. (now a member of Nikkiso Co., Ltd.) member companies manufacture engineered cryogenic gas processing equipment and small–scale process plants for the liquefied natural gas (LNG), well services and industrial gas industries. Founded over 50 years ago, Cryogenic Industries is the parent company of ACD, Cosmodyne and Cryoquip and a commonly controlled group of approximately 20 operating entities.

For more information please visit www.nikkisoCEIG.com and www.nikkiso.com.

MEDIA CONTACT:
Anna Quigley
+1.951.383.3314
aquigley@cryoind.com


GLOBENEWSWIRE (Distribution ID 8512532)

EDU FINAL DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages New Oriental Education & Technology Group Inc. Investors with Losses to Secure Counsel Before Important April 5 Deadline in Securities Class Action – EDU

NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of New Oriental Education & Technology Group Inc. (NYSE: EDU) between April 24, 2018 and July 22, 2021, inclusive (the "Class Period"), of the important April 5, 2022 lead plaintiff deadline.

SO WHAT: If you purchased New Oriental Education securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the New Oriental Education class action, go to https://rosenlegal.com/submit–form/?case_id=3117 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 5, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) New Oriental Education's revenue and operational growth was the result of deceptive marketing tactics and abusive business practices that flouted Chinese regulations and policies and exposed New Oriental Education to an extreme risk that more draconian measures would be imposed on New Oriental Education; (2) New Oriental Education had engaged in misleading and fraudulent advertising practices, including the provision of false and misleading discount information designed to obfuscate the true cost of New Oriental Education's programs to its customers; (3) New Oriental Education had falsified teacher qualifications and experience to increase student enrollments; (4) New Oriental Education had defied prior government warnings against linking school enrollments with the provision of private tutoring services; (5) as a result, New Oriental Education was subject to an extreme undisclosed risk of adverse enforcement actions, regulatory fines and penalties, and the imposition of new rules and regulations adverse to New Oriental Education's business and interests; (6) the new rules, regulations, and policies to be implemented by the Chinese government following the Two Sessions parliamentary meetings were far more severe than represented to investors by defendants and in fact posed an existential threat to New Oriental Education and its business; and (7) consequently, defendants' positive statements about New Oriental Education's business, operations, and prospects were materially misleading and lacked a reasonable factual basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the New Oriental Education class action, go to https://rosenlegal.com/submit–form/?case_id=3117 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8512212)

Gene-Editing Technologies, Fluid Mechanics Breakthroughs, and Solutions to Unfathomable Mathematical Equations Recognized by King Faisal Prize

Riyadh, March 29, 2022 (GLOBE NEWSWIRE) — Two mathematicians and a scientist were among this year's King Faisal Prize's seven laureates who received their prizes on 29 March in Riyadh, Saudi Arabia, for having enriched humanity with key and invaluable achievements and discoveries, and excelled in the fields of Medicine, Science, Arabic Language & Literature, and Serving to Islam.

The Medicine Prize was awarded to Professor David Liu, Richard Merkin Professor and Director of the Merkin Institute of Transformative Technologies in Healthcare, who invented the first gene "base editor" in 2016.

This technology laid the foundation for possibly treating thousands of genetic diseases like sickle cell disease and muscular dystrophy. Professor David Liu used "base editors" in mice to correct the genetic mutation behind progeria, a rare condition characterized by premature aging, retarded development, and early death. Still, more work needs to be done before gene "base editors" can be used in humans.

Initiating a revolution in genome editing, "base editors" have received great global demand. They were distributed over 9,000 times to more than 3,000 laboratories around the world. Scientists were able to publish more than 300 papers on this technique, used in different organisms ranging from bacteria to mice.

"Base editing" is a precise genome editing method; like a genetic pencil, that rewrites DNA base letters, which cause genetic mutations and potentially genetic diseases. This technology, which is in constant development, chemically rewrites one DNA base to another by rearranging the atoms of one DNA base to resemble a different base. In 2019, Professor David Liu created with his team "prime editing" which offers more targeting flexibility and greater editing precision.

With over 75 issued U.S. patents, Professor Liu was referred to as the "Gene Corrector" by Nature magazine topping its list of "Ten People Who Mattered This Year" in 2017 and was included in the "Foreign Policy Leading Global Thinkers list". He is also a biotech entrepreneur, cofounding "Editas Medicine", which uses CRISPR therapies (tool for editing genomes) to "discover, develop, manufacture, and commercialize transformative, durable, and precise genomic medicines for a broad class of diseases".

The Science Prize (Mathematics) was awarded jointly to Professor"Martin Hairer, Chair in Probability and Stochastic Analysis at Imperial College's Department of Mathematics, and to Professor"Nader Masmoudi, a distinguished Professor of Mathematics at the New York University of Abu Dhabi and head of his Research Center on Stability, Instability and Turbulence.

Professor Martin Hairer developed the theory of regularity structures which gave a precise mathematical meaning to several equations that were previously outside the scope of mathematical analysis. He published his theory in 2014 providing tools and manuals for solving many previously incomprehensible equations called the stochastic partial differential equations (SPDEs). These equations involve chance and describe how randomness throws disorder into different phenomena like coin tossing, stock price changes, wind movement in a tunnel, or forest fire growth. He transformed the area of SPDEs by introducing fundamental new techniques and was able to solve equations like KPZ equation which describes the evolution of the boundary at which two substances meet over time.

Professor Hairer is a world leader in probability theory and analysis and has authored a monograph and over 100 research articles. His work has been distinguished with several prizes and awards, most notably the LMS Whitehead and Philip Leverhulme prizes in 2008, the Fermat prize in 2013, the Frhlich prize and the Fields Medal in 2014, a knighthood in 2016, and the Breakthrough prize in Mathematics in 2020.

As for Professor Nader Masmoudi, he was able to unlock the mystery around many physics problems which remained unsolved for centuries. He found a flaw in "Euler's" mathematical equations which for more than two centuries described the motions of fluids under any circumstance. He discovered that Euler's equations do not apply to all circumstances, as previously thought, and proved that they could break or fail under certain conditions related to fluids. His work helped solve and understand many problems related to fluid–modeling like weather predictions and airplane turbulence.

For the past 20 years, Professor Masmoudi's research has been at the forefront of Partial Differential Equations, Fluid Mechanics, and Dynamical Systems. He has been cited by more than 8000 papers for his works in pure and applied mathematics. He has been recognized with numerous awards, including the Best Scientific Paper Award in Annales de l'Institue Henri Poincar, a Chair from the Fondation Sciences Mathematiques de Paris, The Fermat Prize, and the Chair Schlumberger from the IHES in Paris.

In addition to Medicine and Science, King Faisal Prize recognized this year the achievements of outstanding thinkers and scholars in the field of Arabic Language & Literature, and honored exemplary leaders who played a pivotal role in serving Islam, Muslims, and humanity at large.

The Arabic Language and Literature Prize about "Arabic Literature Studies in English" was awarded to Professor Suzanne Stetkevych, Chair of the Department of Arabic & Islamic Studies at Georgetown University, and to Professor Muhsin Al–Musawi, Professor of Arabic and Comparative Literary Studies at Columbia University.

Professor Suzanne Stetkevych was awarded the prize for her extensive research and work analyzing Arabic literature with unmatched depth from the pre–Islamic period to the revivalist period. Her research approach resulted in the renewal of the critical perspective and methods of studying classical Arabic poetry.

Professor Muhsin Al–Musawi received the prize for being a well–established authority in the field of Arabic literature demonstrating his encyclopedic knowledge in both classical and modern Arabic literature. His research and studies have made great impact on students and researchers in the field of Arabic studies, both in the Arab world and the West. He handled Arabic literature as a world literature.

The Service to Islam Prize was awarded to the former Tanzanian President His Excellency Ali Hassan Mwinyi and to Professor Hassan Mahmoud Al Shafei. His Excellency Ali Hassan Mwinyi actively participated in Islamic advocacy, spreading the spirit of religious tolerance, educating Muslims, and translating many Islamic resources and references into Swahili language. In parallel, Professor Hassan Mahmoud Alshafei served Islamic sciences through teaching, writing, authenticating, and translating, and has contributed to the establishment of the International Islamic University in Islamabad and the development of its colleges' curricula.

The Islamic Studies Prize for this year on "Islamic Heritage of Al– Andalus" was withheld because the nominated works did not meet the criteria of the prize.

Since 1979, King Faisal Prize in its 5 different categories has awarded 282 laureates from 44 different nationalities who have made distinguished contributions to different sciences and causes. Each prize laureate is endowed with USD 200 thousand; a 24–carat gold medal weighing 200 grams, and a Certificate inscribed with the Laureate's name and a summary of their work which qualified them for the prize.

Attachments


GLOBENEWSWIRE (Distribution ID 8512442)

TLS FINAL DEADLINE ALERT: ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Telos Corporation Investors with Losses in Excess of $100K to Secure Counsel Before Important April 8 Deadline in Securities Class Action – TLS

NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Telos Corporation (NASDAQ: TLS) between November 19, 2020 and November 12, 2021, inclusive (the "Class Period"), of the important April 8, 2022 lead plaintiff deadline.

SO WHAT: If you purchased Telos securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Telos class action, go https://rosenlegal.com/submit–form/?case_id=3147 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 8, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the TSA and CMS contracts, which constituted a majority of Telos' future revenues, were not on track to commence as represented at the end of 2021 and in 2022; (2) defendants lacked a reasonable basis and sufficient visibility to provide and affirm Telos' 2021 guidance in the face of the uncertainty surrounding the TSA and CMS contracts; (3) COVID–19 and hacking scandal–related headwinds were throwing off the timing for performance of the TSA and CMS contracts and their associated revenues; (4) as a result, the guidance provided by defendants was not in fact "conservative"; (5) as a result of the delays, Telos would be forced to dramatically reduce its revenue estimates; and (6) as a result of the foregoing, defendants' statements about Telos' business, operations, and prospects, were materially false and/or misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Telos class action, go https://rosenlegal.com/submit–form/?case_id=3147 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8512201)

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages TaskUs, Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action – TASK

NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of TaskUs, Inc. (NASDAQ: TASK) between June 11, 2021 and January 19, 2022, inclusive (the "Class Period"), of the important April 25, 2022 lead plaintiff deadline.

SO WHAT: If you purchased TaskUs securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the TaskUs class action, go to https://rosenlegal.com/submit–form/?case_id=3647 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 25, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) TaskUs was experiencing severe financial strain and business challenges, particularly with its most important customer Facebook; (2) the Content Security market was smaller than defendants represented and defendants' representations were based on outdated market data; (3) TaskUs improperly recognized revenue from certain key contracts; (4) defendants overstated the size of TaskUs' workforce as well as employee retention rates, and understated attrition rates; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the TaskUs class action, go to https://rosenlegal.com/submit–form/?case_id=3647 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8512256)

TAL FINAL DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages TAL Education Group Investors with Losses in Excess of $100K to Secure Counsel Before Important April 5 Deadline in Securities Class Action – TAL

NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of TAL Education Group (NYSE: TAL) between April 26, 2018 and July 22, 2021, inclusive (the "Class Period"), of the important April 5, 2022 lead plaintiff deadline.

SO WHAT: If you purchased TAL Education securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the TAL Education class action, go to https://rosenlegal.com/submit–form/?case_id=3137 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 5, 2022. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) TAL Education's revenue and operational growth was the result of deceptive marketing tactics and illicit business practices that flouted Chinese laws, regulations, and policies, and exposed TAL Education to an extreme risk that more draconian measures would be imposed on TAL Education; (2) TAL Education had engaged in misleading and fraudulent advertising practices, including the provision of false and misleading discount information designed to obfuscate the true cost of TAL Education's programs to its customers, the creation of fake customer reviews designed to fraudulently lure new customers to TAL Education programs, the misrepresentation of teacher qualifications and course qualities, and the marketing of rigged promotional events; (3) TAL Education had defied Chinese policies designed to alleviate the burden imposed by tutoring services on students and their families, including by imposing hefty advances and recurring debt payments on course enrollees, by offering courses designed to give affluent students unfair advantages, by holding courses outside of allowable tutoring hours, and by linking for–profit courses to government–mandated schooling; (4) as a result, TAL Education was subject to an extreme undisclosed risk of adverse enforcement actions, regulatory fines, and penalties, and the imposition of new rules and regulations adverse to TAL Education's business and financial interests; and (5) consequently, TAL Education's historical growth was not sustainable or the result of legitimate business tactics as represented, and defendants' positive statements about TAL Education's business, operations, and prospects were materially false and misleading and lacked a reasonable factual basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the TAL Education class action, go to https://rosenlegal.com/submit–form/?case_id=3137 or call Phillip Kim, Esq. toll–free at 866–767–3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the–rosen–law–firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

———————————————–

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686–1060
Toll Free: (866) 767–3653
Fax: (212) 202–3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com


GLOBENEWSWIRE (Distribution ID 8512205)